Rosetta Puts Blood-Based Cancer Screen on Back Burner to Refocus on miRNA Diagnostics

The news wasn't a complete surprise given the general difficulties in measuring and interpreting blood-borne miRNA signatures, as well as the firm's own admission in September that "technical obstacles" had been stymieing its efforts to develop the screen.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.